Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Diagnostics Regains Nasdaq Compliance

NEW YORK (GenomeWeb) – Interpace Diagnostics today said that it has regained compliance with a Nasdaq listing requirement calling for at least $2.5 million in stockholder equity.

As a result, the company's shares will remain listed on the Nasdaq Capital Market.

The firm was notified in November that it failed to meet the listing requirement and faced delisting action. On April 10, though, it received a letter from Nasdaq saying it had regained compliance.

In January, Interpace regained compliance on another listing requirement calling for a minimum $1 bid price per share. The company effected a 1-for-10 reverse stock split in December in order to meet that requirement.

In early morning trading, Interpace's shares rose about 3 percent to $2.25. 

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.